 Phase 1 Single-Dose Data Show Uptake Across Multiple Tumor Types; No Dose Limiting Toxicities or Treatment-Related Serious Adverse Events HAMILTON, ON and BOSTON, Dec. 10, 2020 PRNewswire -- Fusion Pharmaceuticals Inc. Nasdaq: FUSN, a clinical-stage oncology company focused on... 